Personalized re-treatment strategy for uveal melanoma local recurrences after interventional radiotherapy (brachytherapy): single institution experience and systematic literature review

Luca Tagliaferri, MD, PhD1, Monica Maria Pagliara, MD2,3, Bruno Fionda, MD1, Andrea Scupola, MD2,3, Luigi Azario4,5, Maria Grazia Sammarco, MD2,3, Rosa Autorino, MD, PhD1, Valentina Lanciotti, MD6, Silvia Cammelli, MD7, Carmela Grazia Caputo, MD6, Rafael Martinez-Monge, MD9, György Kovács, MD, PhD10, Maria Antonietta Gambacorta, MD, PhD11, Vincenzo Valentini, MD11, Maria Antonietta Blasi, MD2,3

1U.O.C. Radioterapia Oncologica, Dipartimento di Diagnostica per immagini, Radioterapia Oncologica ed Ematologia, Fondazione Polyclinico Universitario “A. Gemelli” IRCCS, Roma, Italy, 2Istituto di Oftalmologia, Università Cattolica del Sacro Cuore, Roma, Italy, 3UOC di Oncologia Oculare, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Roma, Italy, 4U.O.C. Fisica Sanitaria, Dipartimento di Diagnostica per immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Roma, Italy, 5Istituto di Fisica, Università Cattolica del Sacro Cuore, Roma, Italy, 6University of Perugia and Perugia General Hospital, Radiation Oncology Section, Perugia, Italy, 7Radiation Oncology Center, Department of Experimental, Diagnostic and Specialty Medicine – DIMES, S. Orsola-Malpighi Hospital, University of Bologna, Italy, 8Istituto di Offalmologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy, 9Clinica Universidad de Navarra, Navarra, Spain, 10Interdisciplinary Brachytherapy Unit, University of Luebeck – University Hospital S-H, Campus Luebeck, Germany, 11Istituto di Radiologia, Università Cattolica del Sacro Cuore, Roma, Italy

Abstract

Purpose: To report the results of a patient’s tailored therapeutic approach using a second course of interventional radiotherapy (brachytherapy) in patients with locally recurrent uveal melanoma.

Material and methods: Patients who had already undergone ocular brachytherapy treated at our IOC (Interventional Oncology Center) were considered. Five patients who has received a second course of treatment with a plaque after local recurrences were included in our study. Re-irradiation was performed with Ruthenium-106 (prescribed dose to the apex 100 Gy) or with Iodine-125 plaques (prescribed dose to the apex 85 Gy). Moreover, a systematic literature search was conducted through three electronic databases, including Medline/PubMed, Scopus, and Embase.

Results: All patients were initially treated with Ruthenium-106 plaque; the re-irradiation was performed with Ruthenium-106 plaque in three cases and with Iodine in two cases. Mean time between the first and the second plaque was 56.8 months (range, 25-93 months). Local tumor control rate was 100%, no patient underwent secondary enucleation owing to re-treatment failure. Distant metastasis occurred in 1 patient after 6 months from re-treatment. After a median follow-up of 44.2 months (range, 26-65 months) from re-treatment, all patients experienced worsening of the visual acuity (median visual acuity was 0.42 at time of recurrence and decline to 0.24 at the most recent follow-up); cataract occurred in two cases, no patient developed scleral necrosis. We considered 2 papers for a systematic review.

Conclusions: In selected cases, especially in presence of marginal local recurrence, a personalized re-treatment strategy with a plaque may offer high probability of tumor control and organ preservation but worsening of visual acuity.

J Contemp Brachytherapy 2019; 11, 1: 1–7
DOI: https://doi.org/10.5114/jcb.2019.82888

Key words: uveal melanoma, brachytherapy, re-treatment, re-irradiation.

Purpose

Episcleral plaque radiotherapy is an effective method of controlling uveal melanoma locally as confirmed by long-term results [1]. Unfortunately, failure of the radioactive plaque to control tumor growth is occasionally observed [2]. Data published in a review by Chang presents local failure rates following various forms of conservative treatments for uveal melanoma [3]: among 49 identified studies, the local treatment failure rate ranged from 0% to 55.6%. The two most widely used forms of interventional radiation therapy, Iodine-125 and Ruthenium-106...
Brachytherapy, were associated with a weighted average of local recurrence rate of 9.6%. Furthermore, proton beams resulted in 4.2%, while transpupillary thermotherapy had the largest reported variation of local treatment failure from 0% to 55.6%, with a weighted average of 20.8%. It is possible to observe different kinds of recurrences and a specific dependence from their growth patterns; they may take the form of marginal, central, diffuse, distant, or extrascleral extensions. Marginal recurrences might be related to an insufficient radiation dose to the tumor border following an underdosage to the tumor’s edge mainly due to the microscopic disease spread or displacement of the plaque.

Distant recurrences are rare, and they might be caused by melanoma cell spreading throughout the anterior chamber or by the extension of the tumor along the ciliary body. As suggested by some authors, they may be present due to the migration of tumor cells into the exudative retinal detachment [4]. The work of Caujolle et al. analyzed the prognosis of different types of uveal melanoma recurrences and reported superior survival rate of marginal recurrence compared to other recurrences in patients treated with proton beams [5].

Usually, the treatment approach for a local recurrence is an enucleation, resulting in several side effects, including poor esthetic results and visual loss [6], which has been investigated and related to tumor localization and dose to the fovea [7]. The main aim of this work is to evaluate outcomes of recurrence re-treatment using eye plaque interventional radiotherapy by analyzing the institutional experience and performing a systematic review of the literature.

**Material and methods**

The records of patients treated between December 2006 and December 2014 at our institutional IOC [8] (Interventional Oncology Center) [9] for primary uveal melanoma were retrospectively reviewed [10]. All patients have been treated with Ruthenium-106 plaques or Iodine-125 seeds, and the tumor’s apex prescription dose was 100 Gy and 85 Gy, respectively. For the treatment, the adequate size and shape of the episcleral plaque has been selected to provide a 1 mm margin in all directions of the base of the tumor. The dose prescription and the CTV definition have been the same for the first course and for the re-treatment. After analyzing all recurrences, patients with marginal recurrences located at the equator, re-treated with the use of interventional radiotherapy were selected for the study.

The exclusion criteria were posterior location of the recurrence and diffuse or global recurrence.

A systematic literature search was conducted through three electronic databases from their inception until February 2018, including Medline/Pubmed, Scopus, and Embase. The following medical subject heading (MeSH) terms were used: “uveal melanoma”, “recurrence”, “brachytherapy” (“uveal melanoma” [supplementary concept] or “uveal melanoma” [all fields], and (“recurrence” [MeSH terms] or “recurrence” [all fields]), and (“brachytherapy” [MeSH terms] or “brachytherapy” [all fields]).
fields[]). Two independent authors (BF, MGS) screened citations at the title and abstract level to identify potentially relevant studies without any duplication. Eligible citations were retrieved for full text review, and any uncertainty was resolved by 2 other radiation oncologist experts from ocular interventional radiotherapy (LT, RA) and 2 ophthalmologist experts of the same field (MMP, AS) from the same institution. An independent review of the data was performed by 4 radiation oncologists (VL, GK, RM, SC) from 4 different radiotherapy centers (Perugia, Lubeck, Navarra, Bologna) and by a medical physicist (LA). The senior members of the Gemelli Ocular Melanoma team dedicated to clinical decision-making in ocular cancer, reviewed the paper and gave the final approval to the manuscript (MAG, VV, MAB).

Results

From our database [11], 23 patients affected by recurrence were considered in this analysis. Among these cases of local recurrences, 14 were treated with enucleation, 1 with trans scleral resection, 3 with proton beam, and 5 were selected to undergo a second cycle of brachytherapy. The characteristics of this radioactive plaque re-treated group of five patients with locally recurrent uveal melanomas are reported in Table 1. The median apex height was 3.33 mm at the time of initial diagnosis and 3.01 at the time of recurrence. The mean time between the first and the second plaque was 56.8 months. All patients were initially treated with Ruthenium-106 plaque. The re-irradiation was performed with Ruthenium-106 plaque in three cases and with Iodine-125 seeds in two cases, and the mean dose delivered to the sclera was 340 Gy in the first treatment and 206 Gy in the second plaque. The choice of the kind of radionuclide was based on the final dose to the sclera. The mean total dose delivered to the sclera was 495 Gy. No patients developed scleral necrosis. After a mean follow-up of 44.2 months, the local tumor control rate was 100%, no patient underwent secondary enucleation owing to re-treatment failure. Distant metastasis occurred in 1 patient after 6 months from re-treatment (Table 2).

All patients experienced worsening of the visual acuity. The median visual acuity at time of local recurrence was 0.42, after a median follow-up of 44.2 months (range, 26-65 months). From the time of re-treatment, all patients evolved, as expected, towards a worsening of the visual acuity, with a median decline to 0.24 at the most recent follow-up. No patient developed scleral necrosis [12]. After the re-treatment, cataract occurred in two cases (Table 3).

Figure 1 presents visible tumor’s regression after treatment of a patient included in the study. In Figure 2, the visual acuity before and after re-treatment at the last follow-up of all patients included in the study are presented. Regarding the systematic review, 103 papers were identified and carefully evaluated, out of which 72 papers were excluded because BT re-irradiation was not the primary topic of the paper, 24 papers were excluded because BT was used as the first line treatment and not in the setting of a recurrence, 4 papers were excluded because authors reported a mixed cases of patients with recurrent disease treated using several modalities, includ-

Table 2. Follow-up outcomes of the patients

| Follow-up from re-treatment (months) | Total dose to sclera (Gy) | Scleral necrosis | Enucleation | Thickness reduction | Metastasis |
|-------------------------------------|---------------------------|-----------------|-------------|--------------------|-----------|
| 1                                   | 65                        | 421.5           | 0           | 0                  | 54.9%     | M0        |
| 2                                   | 38                        | 790.6           | 0           | 0                  | 11%       | M0        |
| 3                                   | 50                        | 309.1           | 0           | 0                  | 53.7%     | M0        |
| 4                                   | 42                        | 471.7           | 0           | 0                  | 37.10%    | M0        |
| 5                                   | 26                        | 483.1           | 0           | 0                  | 22.84%    | M1        |
| Mean                                | 44.2                      | 495.20          | 0           | 0                  | 35.9%     | 1/5 (20%) |

Table 3. Visual acuity throughout follow-up

| Radionuclide | Visual acuity at time of recurrence | Follow-up from re-treatment (months) | Radionuclide | Visual acuity at last follow-up after re-treatment | Cataract |
|--------------|------------------------------------|-------------------------------------|--------------|--------------------------------------------------|---------|
| 1            | Ru-106                             | 50                                  | Ru-106       | 20/40                                            | 1       |
| 2            | Ru-106                             | 40                                  | I-125        | Counting finger                                  | 0       |
| 3            | Ru-106                             | 50                                  | Ru-106       | 20/80                                            | 0       |
| 4            | Ru-106                             | 42                                  | Ru-106       | 20/160                                           | 1       |
| 5            | Ru-106                             | 26                                  | Ru-106       | 20/40                                            | 0       |
| Mean         | 20/50                              | 44.2                                | 20/80        |                                                  |         |
Figure 1. A, B) Choroidal melanoma before and after treatment, showing the appearance of an extensive scar area; C, D) Ultrasoundography (USG) shows tumor’s regression after treatment.

Figure 2. Differences in visual acuity at the time of recurrence and after retreatment.

Figure 3. Search results of literature.
ing BT with Ru-106, but with no chance to extrapolate the specific data. Eventually, only two papers dealing with the specific topic of our review were found (Figure 3).

Discussion

Local tumor control is a critical goal in patients’ management of the entire head and neck region [13], especially in case of choroidal melanoma, since patients with local treatment failure are prone to an increased risk of metastasis and an increased morbidity of an eye and vision [14].

As there is no established management for cases of local treatment failure, the therapeutic approach depends on the extent and the location of the recurrence and remains a case-by-case decision; even though enucleation is still the most used procedure for recurrent melanoma [15].

Important tumor and treatment features [16,17] as well as the total dose of treatment may influence the outcomes (as reported in literature) of both Iodine-125 [18] and Ruthenium-106 [19,20]. That is why there is an increasing evidence in literature towards supporting a personalized approach for shaping target-specific dose distributions [21].

In this study, we report our single institution experience about the use of a second course of brachytherapy for the re-treatment of patients with choroidal melanoma recurrences. The enrolled patients were selected according the following criteria: the presence of a marginal recurrence and a non-posterior localization of the tumor.

Patients with a diffuse or global recurrence were not considered eligible for re-treatment with plaque, since these types of recurrences are not easily covered by a plaque and might cause tumor re-growth.

Patients with posterior tumor recurrence can be elected for proton beam re-treatment or enucleation, since more posterior or close to the optic disc tumor locations are more challenging; plaques cannot be placed accurately to cover the tumors [22]. Moreover, during brachytherapy treatment for posterior uveal melanomas, Almony et al. [23] reported that posterior tilting of a plaque is an important factor contributing to local failure. The tilting and the consequent higher failure rate for posterior tumors could be explained by the difficult surgical access and visualization caused by the orbital anatomy. Furthermore, the optic nerve sheath caused by the obstruction as well the compression of the inferior oblique muscle, the posterior ciliary vessels, and nerves can impede to achieve a close plaque placement to the sclera [24].

In our opinion, in the cases of a re-treatment with plaques, there is an increased risk of posterior tumors tilting, although, in our practice, we use intraoperative ultrasonography for optimal plaque placement [25].

Additionally, epibulbar tissue and inferior oblique muscle fibrosis caused by the first irradiation may create problems to achieve a close apposition of the plaque to the sclera during a second treatment procedure. For these reasons, we excluded the posterior uveal melanoma recurrence from the second course of brachytherapy treatment. In patients with marginal recurrences, the failure of the first brachytherapy might be due to an insufficient radiation dose to the tumor border following errors in treatment planning or in the irradiation delivery, as mentioned by Desjardins et al. [26]. Moreover, as suggested by Caujolle et al. [5], very large or thin melanomas are more likely to reappear, because of the difficulty to properly define the lateral tumor limits by an ultrasound. In an analysis of prognosis of different types of uveal melanoma recurrences, the same authors reported superior survival rate of marginal recurrences compared to that of the other recurrences in patients treated with proton beams. Marucci et al. [27] supposed that the marginal recurrences represent a less aggressive subtype or phenotype than the other recurrences, as they found lower mortality rate in patients with marginal recurrences treated with a second course of proton beam than in recurrences treated with enucleation. We found only two papers dealing with the specific topic of our review (Figure 2). Gaspar de Souza Neves et al. [28] report seven patients who underwent re-irradiation with Ru-106 plaque for uveal melanoma recurrences. The median time between the first treatment and re-irradiation was 24 months and after a median follow-up of 30 months, they found 87.5% of 2-year local control and 60% of progression-free survival. In terms of side effects, the authors specified that all patients evolved with worsening of the visual acuity and cataract; other observed complications were maculopathy and glaucoma. In another study by King et al. [29] included twenty-seven patients who were re-irradiated with I-125, the median follow-up from initial treatment was 100 months, with a median time to local recurrence of 43 months. The median follow-up after re-treatment was 47 months and the reported 5-year local control was 77.2%. Furthermore, the authors reported that the visual acuity was 20/70 (20/20 to counting fingers at 1 foot) at the time of recurrence and declined to count fingers (20/25 to hand motion) at their most recent follow-up examination. A comprehensive view of these data is shown in Table 4. In his study, Gaspar de Souza Neves et al. [28] did not specify the kind of recurrence, while 44.4% of patients re-treated with plaque studied by King et al. [29] were diagnosed with marginal recurrences and 55% by diffuse recurrence. No differenc-

| Table 4. Studies available in literature about uveal melanoma retreated with brachytherapy |
|---|
| Author          | Year | No of patients | Radionuclide used for re-irradiation | FU                | Local control |
|-----------------|------|----------------|-------------------------------------|------------------|---------------|
| Tagliaferri et al. | 2019 | 5              | Ru-106 or I-125                     | 44.2 months      | 100% at 3 years |
| King et al. [29] | 2017 | 27             | I-125                               | 47 months        | 87.5% at 2 years |
| Gaspar de Souza Neves et al. [28] | 2014 | 7              | Ru-106 or I-125                     | 30 months        | 77.2% at 5 years |
es were reported from the latter author among the local control in the two groups. In the light of the above considerations, marginal recurrences appear to be the most adequate indications for re-treatments with plaques [30]. Supported by our experience, we suggest that clinical implementation of validated nomograms [31] based on large patient cohorts may contribute to a better patient selection [32]. There are existing experiences in the literature regarding similar approaches for data collection and sharing [33], especially in the head and neck region [34].

In the presented study, local tumor control after a mean follow-up of 44.2 months was 100% and no patients underwent a secondary enucleation due to re-treatment failure. Distant metastasis occurred in 1 patient after six months. As reported by Marucci et al. [27], the survival in the re-irradiated patients was not compromised by a second course of irradiation. In our study, all patients were initially treated with Ruthenium plaques, and were re-irradiated with Ruthenium-106 plaque in three cases and with Iodine-125 in two cases. In second procedure, the mean total dose delivered to the sclera was 495 Gy. The therapeutic approach was personalized in order to obtain the best functional and local control outcomes [35]. No patients developed scleral necrosis during follow-up. Scleral necrosis is an uncommon complication of radiation therapy because of the radiosensitive nature of this avascular, hypocellular, and relatively inactive tissue [36]. It has been reported as a side effect of brachytherapy, with an incidence of up to 14% [37]. After Iodine-125 plaque radiotherapy of melanomas, Shields et al. [2] found 1% of cases with scleral melting, all included cases of ciliochoroidal melanomas, two of which had a temporarily rectus muscle disinsertion. Although second course of brachytherapy allows the preservation of an eyeball, the procedure may increase ocular morbidity and the risk of vision-threatening ocular side effects. In our patient cohort, cataract occurred in two patients after re-treatment. After a median follow-up of 44.2 (range, 26-65) from re-treatment, all patients evolved with worsening of the visual acuity: median visual acuity was 0.42 at the time of recurrence and declined to 0.24 at the most recent follow-up.

**Conclusions**

In summary, our experience and the systematic review suggest that, in selected cases (especially in the presence of marginal local recurrences), a personalized re-treatment approach with plaques may offer high probability of tumor control and eye preservation, but a worsening of the visual function may occur.

**Disclosure**

Authors report no conflict of interest.

**References**

1. Rao YJ, Sein J, Badiyan S et al. Patterns of care and survival outcomes after treatment for uveal melanoma in the post-com era (2004-2013): a surveillance, epidemiology, and end results analysis. J Contemp Brachytherapy 2017; 9: 453-465.
2. Shields CL, Shields JA, Karlsson U et al. Reasons for enucleation after plaque radiotherapy for posterior uveal melanoma. Clinical findings. Ophthalmology 1989; 96: 919-923.
3. Chang MY,McCannel TA. Local treatment failure after globe-conserving therapy for choroidal melanoma. Br J Ophthalmology 2013; 97: 804-811.
4. Desjardins L. Choroidal melanoma. Rev Infarm 2016; 219: 23-24.
5. Caujolle JP, Paoli V, Chamorey E et al. Local recurrence after uveal melanoma proton beam therapy: recurrence types and prognostic consequences. Int J Radiat Oncol Biol Phys 2013; 85: 1218-1224.
6. Melia M, Moy CS, Reynolds SM et al. Quality of life after iodine 125 brachytherapy vs enucleation for choroidal melanoma: 5-year results from the Collaborative Ocular Melanoma Study: COMS QOLS Report No. 3. Arch Ophthalmol 2006; 124: 226-238.
7. Miguel D, De Frutos-Baraja JM, López-Lara F et al. Visual outcome after posterior uveal melanoma episcleral brachytherapy including radiobiological doses. J Contemp Brachytherapy 2018; 10: 123-131.
8. Tagliaferri L, Kovács G, Autorino R et al. ENT COBRA (Consortium for Brachytherapy Data Analysis): interdisciplinary standardized data collection system for head and neck patients treated with interventional radiotherapy (brachytherapy). J Contemp Brachytherapy 2016; 8: 336-343.
9. Kovács G, Tagliaferri L, Valentinii V. Is an Interventional Oncology Center an advantage in the service of cancer patients or in the education? The Gemelli Hospital and INTERACTS experience. J Contemp Brachytherapy 2017; 9: 497-498.
10. Tagliaferri L, Pagliara MM, Boldrini L et al. INTERACTS (INTERventional Radiotherapy ACTive Teaching School) guidelines for quality assurance in choroidal melanoma interventional radiotherapy (brachytherapy) procedures. J Contemp Brachytherapy 2017; 9: 287-295.
11. Valentinii V, Maurizi F, Tagliaferri L et al. Spider: managing clinical data of cancer patients treated through a multidisciplinary approach by a palm based system. Italian Journal of Public Health 2012; 5: 154-164.
12. Tagliaferri L, Pagliara MM, Masiocchii C et al. Nomogram for predicting radiation maculopathy in patients treated with Ruthenium106 plaque brachytherapy for uveal melanoma. J Contemp Brachytherapy 2017; 9: 540-547.
13. Tagliaferri L, Busu F, Fionda B et al. Perioperative HDR brachytherapy for reirradiation in head and neck recurrences: single-institution experience and systematic review. Tu- mori 2017; 103: 516-524.
14. Stmad V, Pötter R, Kovács G et al. Practical handbook of brachytherapy. Bremen UNI-MED Verl. 2014.
15. Seibel I, Cordini D, Rehak M et al. Local recurrence after primary proton beam therapy in uveal melanoma: risk factors, retreatment approaches, and outcome. Am J Ophthalmol 2015; 160: 628-636.
16. Miguel D, De Frutos-Baraja JM, López-Lara F et al. Radiobiological doses, tumor, and treatment features influence on local control, enucleation rates, and survival after episcleral brachytherapy. A 20-year retrospective analysis from a single-institution: part I. J Contemp Brachytherapy 2018; 10: 337-346.
17. Miguel D, De Frutos-Baraja JM, López-Lara F et al. Radiobiological doses, tumor, and treatment features influence on outcomes after episcleral brachytherapy. A 20-year retrospective analysis from a single-institution: part II. J Contemp Brachytherapy 2018; 10: 347-359.
18. Kowal J, Markiewicz A, Dębicka-Kumela M et al. Outcomes of 1-125 brachytherapy for uveal melanomas depending on irradiation dose applied to the tumor apex - a single institution study. J Contemp Brachytherapy 2018; 10: 532-541.
19. Rospond-Kubiak I, Wróblewska-Zierhofer M, Twardosz-Pawluk H et al. Ruthenium brachytherapy for uveal melano-
nom – single institution experience. J Contemp Brachytherapy 2017; 9: 548-552.
20. Naseripour M, Jaberí R, Sedaghat A et al. Ruthenium-106 brachytherapy for thick uveal melanoma: reappraisal of apex and base dose radiation and dose rate. J Contemp Brachytherapy 2016; 8: 66-73.
21. Gagne NL, Cutright DR, Rivard MJ. Keeping an eye on the ring: COMS plaque loading optimization for improved dose conformity and homogeneity. J Contemp Brachytherapy 2012; 4: 165-175.
22. Chang MY, McCannel TA. Local treatment failure after globe-conserving therapy for choroidal melanoma. Br J Ophthalmol 2013; 97: 804-811.
23. Almony A, Breit S, Zhao H et al. Tilting of radioactive plaques after initial accurate placement for treatment of uveal melanoma. Arch Ophthalmol 2008; 126: 65-70.
24. Harbour JW, Murray TG, Byrne SF et al. Intraoperative echographic localization of iodine 125 episcleral radioactive plaques for posterior uveal melanoma. Retina 1996; 16: 129-134.
25. Finger PT, Romero JM, Rosen RB et al. Three-dimensional ultrasonography of choroidal melanoma: localization of radioactive eye plaques. Arch Ophthalmol 1998; 116: 305-312.
26. Desjardins L, Lumbroso L, Levy C et al. Treatment of uveal melanoma with iodine 125 plaques or proton beam therapy: indications and comparison of local recurrence rates. J Fr Ophthalmol 2003; 26: 269-276.
27. Marucci L, Lane AM, Li W et al. Conservation treatment of the eye: Conformal proton reirradiation for recurrent uveal melanoma. Int J Radiat Oncol Biol Phys 2006; 64: 1018-1022.
28. Gaspar de Souza Neves DF, Ferragut MA, Ferreira DV et al. Reirradiation of the eye with plaque brachytherapy: a single institution experience report of eight consecutive patients submitted to retreatment after local relapse of malignant disease of the eye. Brachytherapy 2014; 13: 281-284.
29. King B, Morales-Tirado VM, Wynn HG et al. Repeat episcleral plaque brachytherapy: clinical outcomes in patients treated for locally recurrent posterior uveal melanoma. Am J Ophthalmol 2017; 176: 40-45.
30. Pagliara MM, Tagliaferri L, Azario L et al. Ruthenium Interventional Radiotherapy (brachytherapy) for uveal melanoma: an analysis of factors favoring the development of radiation complications. Brachytherapy 2018; 17: 432-438.
31. Damiani A, Masciocchi C, Boldrini L et al. Preliminary data analysis in healthcare multicentric data mining: a privacy-preserving distributed approach. JE-LKS. Journal of E-learning and Knowledge Society 2018; 14. ISSN: 1826-6223.
32. Meldolesi E, Van Soest J, Alitto AR et al. VATE: VAlidation of high TEchnology based on large database analysis by learning machine. Future Medicine 2014; 3: 435-450.
33. Tagliaferri L, Gobitti C, Colloca GF et al. A new standardized data collection system for interdisciplinary thyroid cancer management: Thyroid COBRA. Eur J Intern Med 2018; 53: 73-78.
34. Tagliaferri L, Badrukkar A, Lenkowicz J et al. ENT COBRA ONTOLOGY: the covariates classification system proposed by the Head & Neck and Skin GEC-ESTRO Working Group for interdisciplinary standardized data collection in head and neck patient cohorts treated with interventional radiotherapy (brachytherapy). J Contemp Brachytherapy 2018; 10: 260-266.
35. Blasi MA, Laguardia M, Tagliaferri L et al. Brachytherapy alone or with neoadjuvant photodynamic therapy for amelanotic choroidal melanoma: functional outcomes and local tumor control. Retina 2016; 36: 2205-2212.
36. Groenewald C, Konstantinidis L, Damato B. Effects of radiotherapy on uveal melanomas and adjacent tissues. Eje (Lond) 2013; 27: 163-171.
37. Chaudhry IA, Liu M, Shamsi FA et al. Corneoscleral necrosis after episcleral Au-198 brachytherapy of uveal melanoma. Retina 2009; 29: 73-79.